Credit Suisse Downgrades United Therapeutics To Underperform

Analysts at Credit Suisse downgraded United Therapeutics

from Neutral to Underperform. The price target for United Therapeutics has been raised from $100 to $120. United Therapeutics shares have surged 44.98% over the past 52 weeks, while the S&P 500 index has gained 14.12% in the same period. United Therapeutics' shares fell 2.51% to close at $131.42 yesterday.